Table of Content
1. INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL MORGELLONS DISEASE MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2. MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL MORGELLONS DISEASE MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY MODELING
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL MORGELLONS DISEASE MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3. MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4. EXECUTIVE SUMMARY
5. PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S FIVE FORCES MODEL
6. INDUSTRY INSIGHTS
6.1 MICRO AND MACRO ECONOMIC FACTORS
6.2 PENETRATION AND GROWTH PROSPECT MAPPING
6.3 KEY PRICING STRATEGIES
6.4 INTERVIEWS WITH SPECIALIST
6.5 ANALYIS AND RECOMMENDATION
7. INTELLECTUAL PROPERTY (IP) PORTFOLIO
7.1 PATENT QUALITY AND STRENGTH
7.2 PATENT FAMILIES
7.3 LICENSING AND COLLABORATIONS
7.4 COMPETITIVE LANDSCAPE
7.5 IP STRATEGY AND MANAGEMENT
7.6 OTHER
8. COST ANALYSIS BREAKDOWN
9. TECHNONLOGY ROADMAP
10. INNOVATION TRACKER AND STRATEGIC ANALYSIS
10.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
10.1.1 JOINT VENTURES
10.1.2 MERGERS AND ACQUISITIONS
10.1.3 LICENSING AND PARTNERSHIP
10.1.4 TECHNOLOGY COLLABORATIONS
10.1.5 STRATEGIC DIVESTMENTS
10.2 NUMBER OF PRODUCTS IN DEVELOPMENT
10.3 STAGE OF DEVELOPMENT
10.4 TIMELINES AND MILESTONES
10.5 INNOVATION STRATEGIES AND METHODOLOGIES
10.6 RISK ASSESSMENT AND MITIGATION
10.7 MERGERS AND ACQUISITIONS
10.8 FUTURE OUTLOOK
11. EPIDEMIOLOGY
11.1 INCIDENCE OF ALL BY GENDER
11.2 TREATMENT RATE
11.3 MORTALITY RATE
11.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
11.5 PATIENT TREATMENT SUCCESS RATES
12. REGULATORY COMPLIANCE
12.1 REGULATORY AUTHORITIES
12.2 REGULATORY CLASSIFICATIONS
12.2.1 CLASS I
12.2.2 CLASS II
12.2.3 CLASS III
12.3 REGULATORY SUBMISSIONS
12.4 INTERNATIONAL HARMONIZATION
12.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS
12.6 REGULATORY CHALLENGES AND STRATEGIES
13. PIPELINE ANALYSIS
13.1 CLINICAL TRIALS AND PHASE ANALYSIS
13.2 DRUG THERAPY PIPELINE
13.3 PHASE III CANDIDATES
13.4 PHASE II CANDIDATES
13.5 PHASE I CANDIDATES
13.6 OTHERS (PRE-CLINICAL AND RESEARCH)
14. REIMBURSEMENT FRAMEWORK
15. OPPUTUNITY MAP ANALYSIS
16. VALUE CHAIN ANALYSIS
17. HEALTHCARE ECONOMY
17.1 HEALTHCARE EXPENDITURE
17.2 CAPITAL EXPENDITURE
17.3 CAPEX TRENDS
17.4 CAPEX ALLOCATION
17.5 FUNDING SOURCES
17.6 INDUSTRY BENCHMARKS
17.7 GDP RATION IN OVERALL GDP
17.8 HEALTHCARE SYSTEM STRUCTURE
17.9 GOVERNMENT POLICIES
17.10 ECONOMIC DEVELOPMENT
18. GLOBAL MORGELLONS DISEASE MARKET, BY DIAGNOSTIC
18.1 OVERVIEW
18.2 PHYSICAL EXAMINATION
18.3 BLOOD TESTS
18.4 SKIN SAMPLES
18.5 OTHERS
19. GLOBAL MORGELLONS DISEASE MARKET, BY THERAPEUTICS
19.1 OVERVIEW
19.2 MEDICATIONS
19.2.1 ANTIPSYCHOTIC DRUGS
19.2.1.1. RISPERIDONE (RISPERDAL)
19.2.1.1.1. DOSAGE STRENGTH
19.2.1.1.1.1 0.25MG
19.2.1.1.1.2 0.5MG
19.2.1.1.1.3 1MG
19.2.1.1.1.4 2MG
19.2.1.1.1.5 3MG
19.2.1.1.1.6 4MG
19.2.1.1.2. DOSAGE FORM
19.2.1.1.2.1 ORAL
19.2.1.1.2.1.1. TABLETS
19.2.1.1.2.1.2. SOLUTION
19.2.1.1.2.1.3. OTHERS
19.2.1.1.2.2 PARENTERAL
19.2.1.1.2.2.1. IM SUSPENSION
19.2.1.1.2.2.2. SC INJECTABLE SUSPENSION
19.2.1.1.2.2.3. OTHERS
19.2.1.2. OLANZAPINE (ZYPREXA)
19.2.1.2.1. DOSAGE STRENGTH
19.2.1.2.1.1 2.5MG
19.2.1.2.1.2 5MG
19.2.1.2.1.3 7.5MG
19.2.1.2.1.4 10MG
19.2.1.2.1.5 15MG
19.2.1.2.1.6 20MG
19.2.1.2.2. DOSAGE FORM
19.2.1.2.2.1 ORAL
19.2.1.2.2.1.1. TABLETS
19.2.1.2.2.1.2. SOLUTION
19.2.1.2.2.1.3. OTHERS
19.2.1.2.2.2 PARENTERAL
19.2.1.2.2.2.1. IM INJECTION
19.2.1.2.2.2.2. OTHERS
19.2.1.3. PIMOZIDE (ORAP)
19.2.1.3.1. 1MG
19.2.1.3.2. 2MG
19.2.1.4. TRIFLUOPERAZINE
19.2.1.5. ESCITALOPRAM
19.2.1.6. DOXEPIN
19.2.2 ANTIBIOTIC
19.2.2.1. DOXYCYCLINE
19.2.2.2. CLINDAMYCIN
19.2.2.3. OTHERS
19.2.3 ANTIDEPRESSANT
19.2.3.1. TRAZODONE
19.2.3.2. NORTRIPTYLINE
19.2.4 ANTIHISTAMINES/ FEXOFENADINE
19.3 OTHERS
20. GLOBAL MORGELLONS DISEASE MARKET, BY ROUTE OF ADMINISTRATION
20.1 OVERVIEW
20.2 ORAL
20.2.1 TABLETS
20.2.2 CAPSULE
20.2.3 OTHERS
20.3 PARENTERAL
20.3.1 INTRAMUSCULAR
20.3.2 SUBCUTANEOUS
20.4 TOPICAL
20.5 OTHERS
21. GLOBAL MORGELLONS DISEASE MARKET, BY DRUG TYPE
21.1 OVERVIEW
21.2 BRANDED
21.2.1 RISPERDAL
21.2.2 ZYPREXA
21.2.3 OTHERS
21.3 GENERICS
22. GLOBAL MORGELLONS DISEASE MARKET, BY PRESCRIPTION MODE
22.1 OVERVIEW
22.2 OVER THE COUNTER
22.3 PRESCRIPTION BASED
23. GLOBAL MORGELLONS DISEASE MARKET, BY PATIENT DEMOGRAPHICS
23.1 OVERVIEW
23.2 PEDIATRIC
23.3 ADULT
23.4 GERIATRIC
24. GLOBAL MORGELLONS DISEASE MARKET, BY GENDER
24.1 OVERVIEW
24.2 MALE
24.2.1 GERIATRIC
24.2.2 ADULT
24.2.3 PEDIATRIC
24.3 FEMALE
24.3.1 GERIATRIC
24.3.2 ADULT
24.3.3 PEDIATRIC
25. GLOBAL MORGELLONS DISEASE MARKET, BY END USERS
25.1 OVERVIEW
25.2 HOSPITAL
25.2.1 BY TYPE
25.2.1.1. PUBLIC
25.2.1.2. PRIVATE
25.2.2 BY LEVEL
25.2.2.1. TIER 1
25.2.2.2. TIER 2
25.2.2.3. TIER 3
25.3 SPECIALTY CENTRES
25.4 AMBULATORY SURGICAL CENTRES
25.5 ACADEMIC AND RESEARCH INSTITUTES
25.6 OTHERS
26. GLOBAL MORGELLONS DISEASE MARKET, BY DISTRIBUTION CHANNEL
26.1 OVERVIEW
26.2 DIRECT TENDER
26.3 RETAIL SALES
26.3.1 ONLINE STORES
26.3.2 OFFLINE STORES
26.4 OTHERS
27. GLOBAL MORGELLONS DISEASE MARKET, COMPANY LANDSCAPE
27.1 COMPANY SHARE ANALYSIS: GLOBAL
27.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
27.3 COMPANY SHARE ANALYSIS: EUROPE
27.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
27.5 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
27.6 MERGERS & ACQUISITIONS
27.7 NEW PRODUCT DEVELOPMENT & APPROVALS
27.8 EXPANSIONS
27.9 REGULATORY CHANGES
27.10 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
28. GLOBAL MORGELLONS DISEASE MARKET, BY REGION
28.1 GLOBAL MORGELLONS DISEASE MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
28.1.1 NORTH AMERICA
28.1.1.1. U.S.
28.1.1.2. CANADA
28.1.1.3. MEXICO
28.1.2 EUROPE
28.1.2.1. GERMANY
28.1.2.2. FRANCE
28.1.2.3. U.K.
28.1.2.4. ITALY
28.1.2.5. SPAIN
28.1.2.6. RUSSIA
28.1.2.7. TURKEY
28.1.2.8. BELGIUM
28.1.2.9. NETHERLANDS
28.1.2.10. SWITZERLAND
28.1.2.11. REST OF EUROPE
28.1.3 ASIA-PACIFIC
28.1.3.1. JAPAN
28.1.3.2. CHINA
28.1.3.3. SOUTH KOREA
28.1.3.4. INDIA
28.1.3.5. AUSTRALIA
28.1.3.6. SINGAPORE
28.1.3.7. THAILAND
28.1.3.8. MALAYSIA
28.1.3.9. INDONESIA
28.1.3.10. PHILIPPINES
28.1.3.11. REST OF ASIA-PACIFIC
28.1.4 SOUTH AMERICA
28.1.4.1. BRAZIL
28.1.4.2. ARGENTINA
28.1.4.3. REST OF SOUTH AMERICA
28.1.5 MIDDLE EAST AND AFRICA
28.1.5.1. SOUTH AFRICA
28.1.5.2. SAUDI ARABIA
28.1.5.3. UAE
28.1.5.4. EGYPT
28.1.5.5. ISRAEL
28.1.5.6. REST OF MIDDLE EAST AND AFRICA
28.1.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
29. GLOBAL MORGELLONS DISEASE MARKET, SWOT AND DBMR ANALYSIS
30. GLOBAL MORGELLONS DISEASE MARKET, COMPANY PROFILE
30.1 PFIZER INC.
30.1.1 COMPANY OVERVIEW
30.1.2 REVENUE ANALYSIS
30.1.3 GEOGRAPHIC PRESENCE
30.1.4 PRODUCT PORTFOLIO
30.1.5 RECENT DEVELOPMENTS
30.2 CHARTWELL PHARMACEUTICALS CONGERS, LLC
30.2.1 COMPANY OVERVIEW
30.2.2 REVENUE ANALYSIS
30.2.3 GEOGRAPHIC PRESENCE
30.2.4 PRODUCT PORTFOLIO
30.2.5 RECENT DEVELOPMENTS
30.3 LUPIN PHARMACEUTICALS, INC.
30.3.1 COMPANY OVERVIEW
30.3.2 REVENUE ANALYSIS
30.3.3 GEOGRAPHIC PRESENCE
30.3.4 PRODUCT PORTFOLIO
30.3.5 RECENT DEVELOPMENTS
30.4 ACTAVIS LABORATORIES FL, INC.
30.4.1 COMPANY OVERVIEW
30.4.2 REVENUE ANALYSIS
30.4.3 GEOGRAPHIC PRESENCE
30.4.4 PRODUCT PORTFOLIO
30.4.5 RECENT DEVELOPMENTS
30.5 ALEMBIC PHARMACEUTICALS LIMITED
30.5.1 COMPANY OVERVIEW
30.5.2 REVENUE ANALYSIS
30.5.3 GEOGRAPHIC PRESENCE
30.5.4 PRODUCT PORTFOLIO
30.5.5 RECENT DEVELOPMENTS
30.6 AMNEAL PHARMACEUTICALS PRIVATE LIMITED
30.6.1 COMPANY OVERVIEW
30.6.2 REVENUE ANALYSIS
30.6.3 GEOGRAPHIC PRESENCE
30.6.4 PRODUCT PORTFOLIO
30.6.5 RECENT DEVELOPMENTS
30.7 HIKMA PHARMACEUTICALS PLC
30.7.1 COMPANY OVERVIEW
30.7.2 REVENUE ANALYSIS
30.7.3 GEOGRAPHIC PRESENCE
30.7.4 PRODUCT PORTFOLIO
30.7.5 RECENT DEVELOPMENTS
30.8 SUN PHARMACEUTICAL INDUSTRIES INC.,
30.8.1 COMPANY OVERVIEW
30.8.2 REVENUE ANALYSIS
30.8.3 GEOGRAPHIC PRESENCE
30.8.4 PRODUCT PORTFOLIO
30.8.5 RECENT DEVELOPMENTS
30.9 ZYDUS LIFESCIENCES LIMITED
30.9.1 COMPANY OVERVIEW
30.9.2 REVENUE ANALYSIS
30.9.3 GEOGRAPHIC PRESENCE
30.9.4 PRODUCT PORTFOLIO
30.9.5 RECENT DEVELOPMENTS
30.10 WELLONA PHARMA
30.10.1 COMPANY OVERVIEW
30.10.2 REVENUE ANALYSIS
30.10.3 GEOGRAPHIC PRESENCE
30.10.4 PRODUCT PORTFOLIO
30.10.5 RECENT DEVELOPMENTS
30.11 TAJ GROUP
30.11.1 COMPANY OVERVIEW
30.11.2 REVENUE ANALYSIS
30.11.3 GEOGRAPHIC PRESENCE
30.11.4 PRODUCT PORTFOLIO
30.11.5 RECENT DEVELOPMENTS
30.12 MMG HEALTHCARE
30.12.1 COMPANY OVERVIEW
30.12.2 REVENUE ANALYSIS
30.12.3 GEOGRAPHIC PRESENCE
30.12.4 PRODUCT PORTFOLIO
30.12.5 RECENT DEVELOPMENTS
30.13 TEVA PHARMACEUTICALS USA
30.13.1 COMPANY OVERVIEW
30.13.2 REVENUE ANALYSIS
30.13.3 GEOGRAPHIC PRESENCE
30.13.4 PRODUCT PORTFOLIO
30.13.5 RECENT DEVELOPMENTS
30.14 CHEPLAPHARM ARZNEIMITTEL GMBH
30.14.1 COMPANY OVERVIEW
30.14.2 REVENUE ANALYSIS
30.14.3 GEOGRAPHIC PRESENCE
30.14.4 PRODUCT PORTFOLIO
30.14.5 RECENT DEVELOPMENTS
30.15 ASPIRO PHARMA LIMITED
30.15.1 COMPANY OVERVIEW
30.15.2 REVENUE ANALYSIS
30.15.3 GEOGRAPHIC PRESENCE
30.15.4 PRODUCT PORTFOLIO
30.15.5 RECENT DEVELOPMENTS
30.16 AMERICAN REGENT, INC.
30.16.1 COMPANY OVERVIEW
30.16.2 REVENUE ANALYSIS
30.16.3 GEOGRAPHIC PRESENCE
30.16.4 PRODUCT PORTFOLIO
30.16.5 RECENT DEVELOPMENTS
30.17 MACLEODS PHARMACEUTICALS LTD.
30.17.1 COMPANY OVERVIEW
30.17.2 REVENUE ANALYSIS
30.17.3 GEOGRAPHIC PRESENCE
30.17.4 PRODUCT PORTFOLIO
30.17.5 RECENT DEVELOPMENTS
30.18 SANDOZ AG
30.18.1 COMPANY OVERVIEW
30.18.2 REVENUE ANALYSIS
30.18.3 GEOGRAPHIC PRESENCE
30.18.4 PRODUCT PORTFOLIO
30.18.5 RECENT DEVELOPMENTS
30.19 ALKEM
30.19.1 COMPANY OVERVIEW
30.19.2 REVENUE ANALYSIS
30.19.3 GEOGRAPHIC PRESENCE
30.19.4 PRODUCT PORTFOLIO
30.19.5 RECENT DEVELOPMENTS
30.20 APOTEX INC
30.20.1 COMPANY OVERVIEW
30.20.2 REVENUE ANALYSIS
30.20.3 GEOGRAPHIC PRESENCE
30.20.4 PRODUCT PORTFOLIO
30.20.5 RECENT DEVELOPMENTS
30.21 EUGIA US LLC
30.21.1 COMPANY OVERVIEW
30.21.2 REVENUE ANALYSIS
30.21.3 GEOGRAPHIC PRESENCE
30.21.4 PRODUCT PORTFOLIO
30.21.5 RECENT DEVELOPMENTS
30.22 QILU PHARMACEUTICAL CO., LTD.
30.22.1 COMPANY OVERVIEW
30.22.2 REVENUE ANALYSIS
30.22.3 GEOGRAPHIC PRESENCE
30.22.4 PRODUCT PORTFOLIO
30.22.5 RECENT DEVELOPMENTS
30.23 ORBION PHARMACEUTICALS PRIVATE LIMITED
30.23.1 COMPANY OVERVIEW
30.23.2 REVENUE ANALYSIS
30.23.3 GEOGRAPHIC PRESENCE
30.23.4 PRODUCT PORTFOLIO
30.23.5 RECENT DEVELOPMENTS
30.24 DR. REDDY’S LABORATORIES LTD.
30.24.1 COMPANY OVERVIEW
30.24.2 REVENUE ANALYSIS
30.24.3 GEOGRAPHIC PRESENCE
30.24.4 PRODUCT PORTFOLIO
30.24.5 RECENT DEVELOPMENTS
30.25 AUROBINDO PHARMA LIMITED
30.25.1 COMPANY OVERVIEW
30.25.2 REVENUE ANALYSIS
30.25.3 GEOGRAPHIC PRESENCE
30.25.4 PRODUCT PORTFOLIO
30.25.5 RECENT DEVELOPMENTS
30.26 JANSSEN PHARMACEUTICAL COMPANIES
30.26.1 COMPANY OVERVIEW
30.26.2 REVENUE ANALYSIS
30.26.3 GEOGRAPHIC PRESENCE
30.26.4 PRODUCT PORTFOLIO
30.26.5 RECENT DEVELOPMENTS
30.27 TORRENT PHARMACEUTICALS LTD.
30.27.1 COMPANY OVERVIEW
30.27.2 REVENUE ANALYSIS
30.27.3 GEOGRAPHIC PRESENCE
30.27.4 PRODUCT PORTFOLIO
30.27.5 RECENT DEVELOPMENTS
30.28 AJANTA PHARMA INC.
30.28.1 COMPANY OVERVIEW
30.28.2 REVENUE ANALYSIS
30.28.3 GEOGRAPHIC PRESENCE
30.28.4 PRODUCT PORTFOLIO
30.28.5 RECENT DEVELOPMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
31. RELATED REPORTS
32. CONCLUSION
33. QUESTIONNAIRE
34. ABOUT DATA BRIDGE MARKET RESEARCH
